ArticleElectrophoresis2009
Quantitative proteomics investigation of pancreatic intraepithelial neoplasia.
Article in Electrophoresis, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 57 citations in OpenAlex.
- Development of a multiplex assay for early detection of pancreatic cancer in high-risk groups.BMC cancer · 2026Article
- SLB-msSIM: A Spectral Library-Based Multiplex Segmented SIM Platform for Single-Cell Proteomic Analysis.Proteomics · 2025Article
- Identification and analysis of pancreatic intraepithelial neoplasia: opportunities and challenges.Frontiers in endocrinology · 2024Review
- The next "sweet" spot for pancreatic ductal adenocarcinoma: Glycoprotein for early detection.Mass spectrometry reviews · 2023Review
- The mechanobiome: a goldmine for cancer therapeutics.American journal of physiology. Cell physiology · 2021Review
- Proteome-wide and matrisome-specific alterations during human pancreas development and maturation.Nature communications · 2021Article
- Proteome alterations in pancreatic ductal adenocarcinoma.Cancer letters · 2020Review
- Proteomic and genomic profiling of pancreatic cancer.Cell biology and toxicology · 2019Review
- The glycosylation landscape of pancreatic cancer.Oncology letters · 2019Review
- Review
- Increased plasma levels of galectin-1 in pancreatic cancer: potential use as biomarker.Oncotarget · 2018Article
- Contribution of galectin-1, a glycan-binding protein, to gastrointestinal tumor progression.World journal of gastroenterology · 2017Review
- Synthesis and functionalization of protease-activated nanoparticles with tissue plasminogen activator peptides as targeting moiety and diagnostic tool for pancreatic cancer.Journal of nanobiotechnology · 2016Article
- Glycoproteins and glycoproteomics in pancreatic cancer.World journal of gastroenterology · 2016Review
- Article
- p120 Catenin Suppresses Basal Epithelial Cell Extrusion in Invasive Pancreatic Neoplasia.Cancer research · 2016Article
- Pancreatic preneoplastic lesions plasma signatures and biomarkers based on proteome profiling of mouse models.British journal of cancer · 2015Article
- Molecular detection of pancreatic neoplasia: Current status and future promise.World journal of gastroenterology · 2015Review
- Proteins associated with pancreatic cancer survival in patients with resectable pancreatic ductal adenocarcinoma.Laboratory investigation; a journal of technical methods and pathology · 2015Article
- Pancreatic cancer and its stroma: a conspiracy theory.World journal of gastroenterology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 7 institutions in 2 countries.
Funding
Abstract
Patients with pancreatic cancer are usually diagnosed at late stages, when the disease is incurable. Pancreatic intraepithelial neoplasia (PanIN) 3 is believed to be the immediate precursor lesion of pancreatic adenocarcinoma, and would be an ideal stage to diagnose patients, when intervention and cure are possible and patients are curable. In this study, we used quantitative proteomics to identify dysregulated proteins in PanIN 3 lesions. Altogether, over 200 dysregulated proteins were identified in the PanIN 3 tissues, with a minimum of a 1.75-fold change compared with the proteins in normal pancreas. These dysregulated PanIN 3 proteins play roles in cell motility, the inflammatory response, the blood clotting cascade, the cell cycle and its regulation, and protein degradation. Further network analysis of the proteins identified c-MYC as an important regulatory protein in PanIN 3 lesions. Finally, three of the overexpressed proteins, laminin beta-1, galectin-1, and actinin-4 were validated by immunohistochemistry analysis. All three of these proteins were overexpressed in the stroma or ductal epithelial cells of advanced PanIN lesions as well as in pancreatic cancer tissue. Our findings suggest that these three proteins may be useful as biomarkers for advanced PanIN and pancreatic cancer if further validated. The dysregulated proteins identified in this study may assist in the selection of candidates for future development of biomarkers for detecting early and curable pancreatic neoplasia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.